617 related articles for article (PubMed ID: 20490655)
21. Prediction of breast cancer prognosis by gene expression profile of TP53 status.
Takahashi S; Moriya T; Ishida T; Shibata H; Sasano H; Ohuchi N; Ishioka C
Cancer Sci; 2008 Feb; 99(2):324-32. PubMed ID: 18271932
[TBL] [Abstract][Full Text] [Related]
22. Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer.
Bertucci F; Borie N; Roche H; Bachelot T; Le Doussal JM; Macgrogan G; Debono S; Martinec A; Treilleux I; Finetti P; Esterni B; Extra JM; Geneve J; Hermitte F; Chabannon C; Jacquemier J; Martin AL; Longy M; Maraninchi D; Fert V; Birnbaum D; Viens P
Breast Cancer Res Treat; 2011 Jun; 127(2):363-73. PubMed ID: 20585850
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
24. p53 as a specific prognostic factor in triple-negative breast cancer.
Chae BJ; Bae JS; Lee A; Park WC; Seo YJ; Song BJ; Kim JS; Jung SS
Jpn J Clin Oncol; 2009 Apr; 39(4):217-24. PubMed ID: 19304743
[TBL] [Abstract][Full Text] [Related]
25. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
26. Typical medullary breast carcinomas have a basal/myoepithelial phenotype.
Jacquemier J; Padovani L; Rabayrol L; Lakhani SR; Penault-Llorca F; Denoux Y; Fiche M; Figueiro P; Maisongrosse V; Ledoussal V; Martinez Penuela J; Udvarhely N; El Makdissi G; Ginestier C; Geneix J; Charafe-Jauffret E; Xerri L; Eisinger F; Birnbaum D; Sobol H; ;
J Pathol; 2005 Nov; 207(3):260-8. PubMed ID: 16167361
[TBL] [Abstract][Full Text] [Related]
27. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer.
Sáez R; Molina MA; Ramsey EE; Rojo F; Keenan EJ; Albanell J; Lluch A; García-Conde J; Baselga J; Clinton GM
Clin Cancer Res; 2006 Jan; 12(2):424-31. PubMed ID: 16428482
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical expression of p53 and c-erbB-2 in breast carcinoma: relation with epidemiologic factors, histologic features and prognosis.
Fernández Aceñero MJ; Farina González J; Arangoncillo Ballesteros P
Gen Diagn Pathol; 1997 Jun; 142(5-6):289-96. PubMed ID: 9228251
[TBL] [Abstract][Full Text] [Related]
29. [Prognostic molecular classification of breast cancers based on gene expression profiling].
Feng YM; Li XQ; Sun BC; Gao XC; Gu L; Niu Y; Hao XS
Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):900-6. PubMed ID: 17533740
[TBL] [Abstract][Full Text] [Related]
30. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
Milburn M; Rosman M; Mylander C; Tafra L
Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
32. A study of high-nuclear-grade breast cancer in Thailand: subclassification and correlation with prognostic factors and immunohistochemical study.
Chaiwun B; Nakrungsee S; Sukhamwang N; Srisukho S
Breast Cancer; 2010; 17(1):35-41. PubMed ID: 19789946
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
[TBL] [Abstract][Full Text] [Related]
34. Integrated gene expression profile predicts prognosis of breast cancer patients.
Li LF; Xu XJ; Zhao Y; Liu ZB; Shen ZZ; Jin WR; Shao ZM
Breast Cancer Res Treat; 2009 Jan; 113(2):231-7. PubMed ID: 18278552
[TBL] [Abstract][Full Text] [Related]
35. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients.
Kwiatkowska E; Teresiak M; Filas V; Karczewska A; Breborowicz D; Mackiewicz A
Clin Cancer Res; 2003 Oct; 9(12):4452-9. PubMed ID: 14555518
[TBL] [Abstract][Full Text] [Related]
36. The prognostic significance of the insulin-like growth factor-1 ligand and receptor expression in breast cancer tissue.
Chong KY; Subramanian A; Mokbel K; Sharma AK
J Surg Oncol; 2011 Sep; 104(3):228-35. PubMed ID: 21480260
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathologic and prognostic evaluation of invasive breast carcinoma molecular subtypes and GATA3 expression.
Demir H; Turna H; Can G; Ilvan S
J BUON; 2010; 15(4):774-82. PubMed ID: 21229645
[TBL] [Abstract][Full Text] [Related]
38. Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation.
Karn T; Pusztai L; Ruckhäberle E; Liedtke C; Müller V; Schmidt M; Metzler D; Wang J; Coombes KR; Gätje R; Hanker L; Solbach C; Ahr A; Holtrich U; Rody A; Kaufmann M
Eur J Cancer; 2012 Jan; 48(1):12-23. PubMed ID: 21741824
[TBL] [Abstract][Full Text] [Related]
39. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
[TBL] [Abstract][Full Text] [Related]
40. Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis.
Finetti P; Cervera N; Charafe-Jauffret E; Chabannon C; Charpin C; Chaffanet M; Jacquemier J; Viens P; Birnbaum D; Bertucci F
Cancer Res; 2008 Feb; 68(3):767-76. PubMed ID: 18245477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
